Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05169190 · ClinicalTrials.gov registry record · NA

Stellate Ganglion Block for PTSD

A NA study of Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.

Active
Registry status
NA
Development phase
410
Enrollment target
6
Study locations

NCT05169190: Active NA study of Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.

NCT05169190 is a NA study of Post Traumatic Stress Disorder that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 410 participants, below the 662-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (38% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05169190, a NA study of Post Traumatic Stress Disorder, is active but no longer recruiting, sponsored by VA Office of Research and Development.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
410 participants
Enrollment target
6
Study locations

Study Summary

Posttraumatic Stress Disorder (PTSD) is a debilitating condition that affects about 15% of Veterans. Current treatments for Veterans with PTSD include medications and psychological therapies that help to process and desensitize to traumatic events. While effective for many, these treatments do not work for all patients, and many may refuse them. Stellate Ganglion Block (SGB), established to treat pain and other conditions, has shown promise for PTSD: early small studies show it may work fast and greatly reduce symptoms. However, data from larger studies are not clear about SGBs effects. A definitive trial is needed, especially for the Veteran population. This large, well-powered, randomized, sham-controlled trial of SGB for PTSD will assess the short-term efficacy of this intervention, the durability of the effects and the safety of the treatment. Additionally, this study will provide critically important information about biological effects of SGB and potential mechanisms of action. This timely study is critical to help VA clinicians better decide about the merits of SGB for PTSD.

Primary Outcome

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured diagnostic interview for PTSD. CAPS-5 items are rated with a single severity score, in contrast to previous versions of the CAPS which required separate frequency and intensity scores for each item that were either summed to create a symptom severity score or combined in various scoring rules to create a dichotomous (present/absent) symptom score. CAPS-5 has 20 symptom items, each rated from 0 (absent) to 4 (severe). There

Conditions Studied

Post Traumatic Stress Disorder

Interventions

  • PROCEDURE Stellate Ganglion Block
  • PROCEDURE Sham Stellate Ganglion Block

Study Locations (6)

California

  • VA Long Beach Healthcare System, Long Beach, CA - Long Beach

Florida

  • James A. Haley Veterans' Hospital, Tampa, FL - Tampa

Minnesota

  • Minneapolis VA Health Care System, Minneapolis, MN - Minneapolis

Utah

  • VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City

Vermont

  • White River Junction VA Medical Center, White River Junction, VT - White River Junction

Wisconsin

  • William S. Middleton Memorial Veterans Hospital, Madison, WI - Madison

Trial Details

FieldValue
Enrollment Target 410 participants
Start Date 2022-11-17
Est. Completion 2026-06-30
Phase NA
VA Office of Research and Development

1,668 total trials

What the registry record for NCT05169190 still lists

NCT05169190 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, below the 662-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (38% lower).

The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Stellate Ganglion Block is the first listed.

NCT05169190 lists 6 locations in 6 states (California, Florida, Minnesota).

Frequently Asked Questions

What is clinical trial NCT05169190 about?

NCT05169190 is a clinical study titled "Stellate Ganglion Block for PTSD". Posttraumatic Stress Disorder (PTSD) is a debilitating condition that affects about 15% of Veterans. Current treatments for Veterans with PTSD include medications and psychological therapies that help to process and desensitize to traumatic events. While effective for many, these treatments do not w...

What is the current status of trial NCT05169190?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2022-11-17. Estimated completion is 2026-06-30.

What conditions does trial NCT05169190 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT05169190?

The interventions under investigation include: Stellate Ganglion Block (PROCEDURE), Sham Stellate Ganglion Block (PROCEDURE).

Who is sponsoring clinical trial NCT05169190?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05169190 being conducted?

This trial has 6 study locations across California, Florida, Minnesota, Utah, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05169190's enrollment target sits among peer trials

410 17th of 262 higher than 245 of 262 other Post Traumatic Stress Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02043691 · 410 participants · NA

    Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

  • NCT03042975 · 410 participants

    Imaging Genetics of Laryngeal Dystonia

  • NCT05730036 · 410 participants · Phase 3

    A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  • NCT06064877 · 410 participants · Phase 3

    A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05169190, the US trial registry maintained by the National Library of Medicine. NCT05169190 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.